Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Expands By 2,750.0%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 11,400 shares, a growth of 2,750.0% from the March 31st total of 400 shares. Based on an average trading volume of 206,900 shares, the short-interest ratio is currently 0.1 days.

Oncotelic Therapeutics Stock Performance

Shares of Oncotelic Therapeutics stock traded up $0.00 on Friday, hitting $0.04. The stock had a trading volume of 22,308 shares, compared to its average volume of 70,737. The company has a quick ratio of 0.02, a current ratio of 0.02 and a debt-to-equity ratio of 0.16. Oncotelic Therapeutics has a one year low of $0.01 and a one year high of $0.05. The stock’s 50-day simple moving average is $0.04 and its two-hundred day simple moving average is $0.04.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.